Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.98
-7.0%		$3.72
$3.10
▼
$7.20
$8.25M136,067 shs31,071 shs
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$0.07
+0.3%		$0.43
$0.07
▼
$4.29
$2.32M0.1917.36 million shs42.29 million shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.95
-1.0%		$1.35
$0.62
▼
$9.65
$6.39M1.72141,416 shs109,055 shs
Immuron stock logo
IMRN
Immuron
$1.03
-1.0%		$1.21
$0.68
▼
$2.39
$8.39M1.0985,539 shs24,850 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-7.01%+10.56%+0.48%-5.01%-31.85%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
0.00%0.00%0.00%-91.48%-97.17%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-1.03%-16.67%-38.71%+13.12%-88.69%
Immuron stock logo
IMRN
Immuron
-0.96%-5.50%-26.43%-8.85%-49.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.98
-7.0%		$3.72
$3.10
▼
$7.20
$8.25M136,067 shs31,071 shs
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$0.07
+0.3%		$0.43
$0.07
▼
$4.29
$2.32M0.1917.36 million shs42.29 million shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.95
-1.0%		$1.35
$0.62
▼
$9.65
$6.39M1.72141,416 shs109,055 shs
Immuron stock logo
IMRN
Immuron
$1.03
-1.0%		$1.21
$0.68
▼
$2.39
$8.39M1.0985,539 shs24,850 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-7.01%+10.56%+0.48%-5.01%-31.85%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
0.00%0.00%0.00%-91.48%-97.17%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-1.03%-16.67%-38.71%+13.12%-88.69%
Immuron stock logo
IMRN
Immuron
-0.96%-5.50%-26.43%-8.85%-49.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.25
Hold$14.50264.32% Upside
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.25
Hold$11.0014,744.80% Upside
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1.80
Reduce$73.007,584.21% Upside
Immuron stock logo
IMRN
Immuron
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BTAI, IMRN, BOLT, and FBLG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Immuron stock logo
IMRN
Immuron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (E+)
8/20/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (E+) ➝ Sell (E)
8/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$8.00 ➝ $6.00
8/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeUnderperform
7/24/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (E+)
7/17/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
7/17/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.70M1.00N/AN/A$13.81 per share0.29
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$640K3.63N/AN/A($4.37) per share-0.02
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$1.85 per shareN/A
Immuron stock logo
IMRN
Immuron
$5.47M1.52N/AN/A$0.94 per share1.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.44N/AN/AN/A-611.47%-126.23%-54.70%11/11/2026 (Estimated)
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$69.90M-$3.79N/AN/AN/A-9,549.87%N/A-185.82%11/11/2026 (Estimated)
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$18.65M-$5.19N/AN/AN/AN/A-536.78%-225.12%10/30/2026 (Estimated)
Immuron stock logo
IMRN
Immuron
-$2.50MN/AN/AN/AN/AN/AN/AN/AN/A

Latest BTAI, IMRN, BOLT, and FBLG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.89N/AN/AN/A$0.07 millionN/A
10/30/2026Q3 2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.63N/AN/AN/AN/AN/A
8/14/2026Q4 2026
Immuron stock logo
IMRN
Immuron
N/A-$0.08N/A-$0.0750N/A$1.27 million
8/13/2026Q2 2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$0.44-$0.49-$0.05-$0.49$0.49 million$0.18 million
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
7/31/2026Q2 2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.93-$0.66+$0.27-$0.66N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
Immuron stock logo
IMRN
Immuron
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
1.47
2.61
2.61
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
0.21
0.21
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
2.64
2.64
Immuron stock logo
IMRN
Immuron
N/A
7.26
5.98

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
30.68%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
Immuron stock logo
IMRN
Immuron
0.12%

Insider Ownership

CompanyInsider Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
3.70%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
7.30%
Immuron stock logo
IMRN
Immuron
7.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
231.93 million1.75 millionNot Optionable
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
9031.31 million30.15 millionNo Data
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
156.66 million6.17 millionN/A
Immuron stock logo
IMRN
Immuron
78.07 million7.51 millionNot Optionable

Recent News About These Companies

Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down
October 13 at 9:01 AM  |  rttnews.comhttps://www.rttnews.com/3698465/immuron-reports-phase-2-travelan-results-published-in-scientific-reports-stock-down.aspx
Immuron Limited Reports Nature Scientific Reports Publication of Phase 2 Travelan Study Showing Reduced ETEC-Related Adverse Events
October 13 at 6:31 AM  |  quiverquant.comQ
Travelan® Phase 2 Study Results Published
October 13 at 6:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379473/37134/en/travelan-phase-2-study-results-published.html
Immuron advances Travelan after Phase 2 data published in Nature journal
October 12 at 6:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immuron-advances-travelan-after-phase-2-data-published-in-nature-journal?utm_source=marketbeat.com&utm_medium=referral
Immuron Ltd ADR (IMRN)
September 26, 2026  |  investing.comhttps://www.investing.com/equities/immuron-ltd-adr-ratios
Immuron Releases Comprehensive 2026 Annual Report
September 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immuron-releases-comprehensive-2026-annual-report?utm_source=marketbeat.com&utm_medium=referral
Immuron Files 2026 Corporate Governance Statement with ASX
September 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immuron-files-2026-corporate-governance-statement-with-asx?utm_source=marketbeat.com&utm_medium=referral
Immuron Showcases Oral Antibody Platform at Coffee Microcaps Conference
September 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immuron-showcases-oral-antibody-platform-at-coffee-microcaps-conference?utm_source=marketbeat.com&utm_medium=referral
Immuron Ltd ADR IMRN
September 9, 2026  |  morningstar.comM
3 Penny Stocks to Watch Today, September 8
September 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/3-penny-stocks-to-watch-today-september-8?utm_source=marketbeat.com&utm_medium=referral
Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS
September 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html
Immuron Stock Surges 56% On U.S. Distribution Deal For PROIBS
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688644/immuron-stock-surges-56-on-u-s-distribution-deal-for-proibs.aspx
IMRN stock skyrockets 60%, heads for best day in over 2 years – what’s driving the super rally today?
September 4, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/imrn-stock-skyrockets-60-heads-for-best-day-in-over-2-years-what-s-driving-the-super-rally-today/ar-AA2bz8sJ
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results
September 4, 2026  |  benzinga.comhttps://www.benzinga.com/markets/market-summary/26/09/61634087/gold-falls-over-1-american-outdoor-brands-shares-jump-after-q1-results
Immuron surges after U.S. PROIBS launch deal adds to recent strong FY26 update
September 4, 2026  |  quiverquant.comQ
Immuron Stock Surges Friday: What's Driving the Action?
September 4, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61626028/immuron-stock-surges-friday-whats-driving-the-action
Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688558/immuron-to-launch-proibs-in-u-s-after-australia-debut-pre-market-shares-up.aspx
Immuron Limited Signs Exclusive U.S. Distribution Agreement for PROIBS with Calmino Group AB
September 4, 2026  |  quiverquant.comQ
Immuron to launch PROIBS® in the United States
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356450/37134/en/immuron-to-launch-proibs-in-the-united-states.html
Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3686519/immuron-fy26-revenue-rises-6-as-net-loss-narrows-and-cash-surges.aspx

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.98 -0.30 (-7.01%)
Closing price 10/14/2026 03:55 PM Eastern
Extended Trading
$3.77 -0.21 (-5.25%)
As of 06:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.95 -0.01 (-1.03%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$0.95 0.00 (-0.11%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Immuron stock logo

Immuron NASDAQ:IMRN

$1.03 -0.01 (-0.96%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$0.98 -0.05 (-4.47%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas